Hannah L. Pellkofer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hannah L. Pellkofer has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Joachim Havla
Institute of Clinical Neuroimmunology, University Hospital, LMU Munich, Munich, Germany
2 shared publications Raymond Voltz
Department of Palliative Care, University of Cologne, 50924 Cologne, Germany
2 shared publicationsA Schulze
Division of Neonatology, Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany
1 shared publicationA. Berthele
From the Institute for Clinical Neuroimmunology (H.L.P., M.K., L.A.G., J.H., R.B., E.M., R.H., T.K.), Department of Neurology (H.L.P.), and Department of Otorhinolaryngology, Head and Neck Surgery (M.C.), Ludwig Maximilians University, Munich; Department of Neuroimmunology (M.K., R.B., E.M.), Max-Planck Institute for Neurobiology, Martinsried; and Department of Neurology (A.B., B.H.), Technische Universität, Munich, Germany
1 shared publication- Achim Berthele
Department of Neurology, School of Medicine and Health, Technical University of Munich, Germany
1 shared publication B. Hemmer
From the Institute for Clinical Neuroimmunology (H.L.P., M.K., L.A.G., J.H., R.B., E.M., R.H., T.K.), Department of Neurology (H.L.P.), and Department of Otorhinolaryngology, Head and Neck Surgery (M.C.), Ludwig Maximilians University, Munich; Department of Neuroimmunology (M.K., R.B., E.M.), Max-Planck Institute for Neurobiology, Martinsried; and Department of Neurology (A.B., B.H.), Technische Universität, Munich, Germany
1 shared publication
Latest Publications
- 25 May 2021
- Published by Springer Nature in Der Schmerz
- Vol. 35 (3) , 211-222
Schmerzen bei multipler Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen
Zusammenfassung Multiple Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen sind autoimmun-entzündliche Erkrankungen des zentralen Nervensystems, die zu vielfältigen neurologischen Beschwerden und Schmerzsyndromen führen können, sowohl akut im Rahmen eines Erkrankungsschubs als auch chronisch, wobei Letzteres die Lebensqualität teils erheblich reduziert. Die Ätiologie der Schmerzen ist sehr heterogen, deren rasche differenzialdiagnostische Zuordnung jedoch entscheidend, um differenzierte Therapiestrategien einleiten zu können. Von Schmerzen als mögliches (frühes) Symptom eines akuten Erkrankungsschubs müssen chronische Schmerzen abgegrenzt, weiter differenziert und individuell behandelt werden. Hierzu zählen zentral-neuropathische und spastikassoziierte Schmerzen, muskuloskeletale Schmerzen durch Fehlbelastung sowie Schmerzen als Nebenwirkungen der Immuntherapien und im Kontext von Komorbiditäten. Aufgrund der mangelhaften Datenlage sind die Therapiestrategien häufig unzureichend evidenzbasiert.
- 25 May 2021
- Published by Springer Nature in Der Schmerz
- Vol. 35 (3) , 211-222
Schmerzen bei multipler Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen
Zusammenfassung Multiple Sklerose und Neuromyelitis-optica-Spektrum-Erkrankungen sind autoimmun-entzündliche Erkrankungen des zentralen Nervensystems, die zu vielfältigen neurologischen Beschwerden und Schmerzsyndromen führen können, sowohl akut im Rahmen eines Erkrankungsschubs als auch chronisch, wobei Letzteres die Lebensqualität teils erheblich reduziert. Die Ätiologie der Schmerzen ist sehr heterogen, deren rasche differenzialdiagnostische Zuordnung jedoch entscheidend, um differenzierte Therapiestrategien einleiten zu können. Von Schmerzen als mögliches (frühes) Symptom eines akuten Erkrankungsschubs müssen chronische Schmerzen abgegrenzt, weiter differenziert und individuell behandelt werden. Hierzu zählen zentral-neuropathische und spastikassoziierte Schmerzen, muskuloskeletale Schmerzen durch Fehlbelastung sowie Schmerzen als Nebenwirkungen der Immuntherapien und im Kontext von Komorbiditäten. Aufgrund der mangelhaften Datenlage sind die Therapiestrategien häufig unzureichend evidenzbasiert.
- Open Access
- 1 May 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (3)
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
Objectives To evaluate prevalence, clinical characteristics, and predictors of pain, depression, and their impact on the quality of life (QoL) in a large neuromyelitis optica spectrum disorder (NMOSD) cohort. Methods We included 166 patients with aquaporin-4–seropositive NMOSD from 13 tertiary referral centers. Patients received questionnaires on demographic and clinical characteristics, PainDetect, short form of Brief Pain Inventory, Beck Depression Inventory–II, and Short Form 36 Health Survey. Results One hundred twenty-five (75.3%) patients suffered from chronic NMOSD-associated pain. Of these, 65.9% had neuropathic pain, 68.8% reported spasticity-associated pain and 26.4% painful tonic spasms. Number of previous myelitis attacks (OR = 1.27, p = 0.018) and involved upper thoracic segments (OR = 1.31, p = 0.018) were the only predictive factors for chronic pain. The latter was specifically associated with spasticity-associated pain (OR = 1.36, p = 0.002). More than a third (39.8%) suffered from depression, which was moderate to severe in 51.5%. Pain severity (OR = 1.81, p < 0.001) and especially neuropathic character (OR = 3.44, p < 0.001) were associated with depression. Pain severity and walking impairment explained 53.9% of the physical QoL variability, while depression and walking impairment 39.7% of the mental QoL variability. No specific medication was given to 70.6% of patients with moderate or severe depression and 42.5% of those with neuropathic pain. Two-thirds (64.2%) of patients with symptomatic treatment still reported moderate to severe pain. Conclusions Myelitis episodes involving upper thoracic segments are main drivers of pain in NMOSD. Although pain intensity was lower than in previous studies, pain and depression remain undertreated and strongly affect QoL. Interventional studies on targeted treatment strategies for pain are urgently needed in NMOSD.
- 1 May 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (3)
Open AccessPain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder
Objectives To evaluate prevalence, clinical characteristics, and predictors of pain, depression, and their impact on the quality of life (QoL) in a large neuromyelitis optica spectrum disorder (NMOSD) cohort. Methods We included 166 patients with aquaporin-4–seropositive NMOSD from 13 tertiary referral centers. Patients received questionnaires on demographic and clinical characteristics, PainDetect, short form of Brief Pain Inventory, Beck Depression Inventory–II, and Short Form 36 Health Survey. Results One hundred twenty-five (75.3%) patients suffered from chronic NMOSD-associated pain. Of these, 65.9% had neuropathic pain, 68.8% reported spasticity-associated pain and 26.4% painful tonic spasms. Number of previous myelitis attacks (OR = 1.27, p = 0.018) and involved upper thoracic segments (OR = 1.31, p = 0.018) were the only predictive factors for chronic pain. The latter was specifically associated with spasticity-associated pain (OR = 1.36, p = 0.002). More than a third (39.8%) suffered from depression, which was moderate to severe in 51.5%. Pain severity (OR = 1.81, p < 0.001) and especially neuropathic character (OR = 3.44, p < 0.001) were associated with depression. Pain severity and walking impairment explained 53.9% of the physical QoL variability, while depression and walking impairment 39.7% of the mental QoL variability. No specific medication was given to 70.6% of patients with moderate or severe depression and 42.5% of those with neuropathic pain. Two-thirds (64.2%) of patients with symptomatic treatment still reported moderate to severe pain. Conclusions Myelitis episodes involving upper thoracic segments are main drivers of pain in NMOSD. Although pain intensity was lower than in previous studies, pain and depression remain undertreated and strongly affect QoL. Interventional studies on targeted treatment strategies for pain are urgently needed in NMOSD.
- 15 June 2018
- Published by Springer Nature
- p. 289-307
Paraneoplastische Erkrankungen
- 1 January 2012
- Published by Springer Nature
- p. 255-271
Paraneoplastische Erkrankungen
- 12 April 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (15) , 1310-1315
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging therapeutic option in NMO. However, neither long-term efficacy or safety of rituximab, nor the correlation between B-cell counts, B-cell fostering cytokines, aquaporin-4 antibodies (AQP4-ab), and disease activity in NMO, have been investigated prospectively. Methods: We performed a prospective long-term cohort study of 10 patients with NMO who were treated up to 5 times with rituximab as a second-line therapy. Clinical examinations, B-cell counts, and serum concentrations of BAFF (B-cell activating factor of the TNF family; also called TNFSF13b), APRIL (a proliferation-inducing ligand; also called TNFSF13), AQP4-ab, and immunoglobulin levels were measured every 3 months. Results: Repeated treatment with rituximab led to sustained clinical stabilization in most patients with NMO. Disease activity correlated with B-cell depletion, but not clearly with AQP4-ab or levels of APRIL. BAFF levels increased after application of rituximab and indicated persisting efficacy of the drug but did not correlate with disease activity. Overall, rituximab was well-tolerated even after up to 5 consecutive treatment courses; however, we observed several severe adverse reactions. Conclusion: Our data indicate that long-term therapy with rituximab is effective in NMO as a second-line therapy and has an acceptable safety profile. Retreatment with rituximab should be applied before reappearance of circulating B cells. Classification of evidence: This study provides Class IV evidence that repeated doses of rituximab result in stabilization in most patients.
- 12 April 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 76 (15) , 1310-1315
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging therapeutic option in NMO. However, neither long-term efficacy or safety of rituximab, nor the correlation between B-cell counts, B-cell fostering cytokines, aquaporin-4 antibodies (AQP4-ab), and disease activity in NMO, have been investigated prospectively. Methods: We performed a prospective long-term cohort study of 10 patients with NMO who were treated up to 5 times with rituximab as a second-line therapy. Clinical examinations, B-cell counts, and serum concentrations of BAFF (B-cell activating factor of the TNF family; also called TNFSF13b), APRIL (a proliferation-inducing ligand; also called TNFSF13), AQP4-ab, and immunoglobulin levels were measured every 3 months. Results: Repeated treatment with rituximab led to sustained clinical stabilization in most patients with NMO. Disease activity correlated with B-cell depletion, but not clearly with AQP4-ab or levels of APRIL. BAFF levels increased after application of rituximab and indicated persisting efficacy of the drug but did not correlate with disease activity. Overall, rituximab was well-tolerated even after up to 5 consecutive treatment courses; however, we observed several severe adverse reactions. Conclusion: Our data indicate that long-term therapy with rituximab is effective in NMO as a second-line therapy and has an acceptable safety profile. Retreatment with rituximab should be applied before reappearance of circulating B cells. Classification of evidence: This study provides Class IV evidence that repeated doses of rituximab result in stabilization in most patients.
- 7 April 2011
- Vol. 153 (14) , 63-6
[Multiple sclerosis: can therapy delay ongoing disability?].
- 1 December 2009
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 217 (1-2) , 90-94
Managing non-paraneoplastic Lambert–Eaton myasthenic syndrome: Clinical characteristics in 25 German patients
- 1 December 2009
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 217 (1-2) , 90-94
Managing non-paraneoplastic Lambert–Eaton myasthenic syndrome: Clinical characteristics in 25 German patients
- 10 August 2009
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (8) , 1006-1008
Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy. In this study, we report the clinical course of a patient with NMO after application of rituximab 1 week before inadvertent conception. Mother and child did not experience any adverse event, and the postpartum development of the baby was completely normal up to 15 months. Clinical course of NMO was stable during the entire pregnancy. This case illustrates a favorable outcome in a pregnant NMO patient and her child after therapy with rituximab.
- 10 August 2009
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 15 (8) , 1006-1008
Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy. In this study, we report the clinical course of a patient with NMO after application of rituximab 1 week before inadvertent conception. Mother and child did not experience any adverse event, and the postpartum development of the baby was completely normal up to 15 months. Clinical course of NMO was stable during the entire pregnancy. This case illustrates a favorable outcome in a pregnant NMO patient and her child after therapy with rituximab.
- 16 July 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (2) , 305-308
Favorable response to rituximab in a patient with anti‐VGCC‐positive Lambert‐Eaton myasthenic syndrome and cerebellar dysfunction
Lambert‐Eaton myasthenic syndrome (LEMS) is an autoimmune disease that is characterized by impaired transmission across the neuromuscular junction due to autoantibodies directed against the presynaptic voltage‐gated calcium channels (VGCC‐ab). Clinical symptoms are usually characterized by proximal muscle weakness and mild dysautonomia. In some patients there are signs of cerebellar dysfunction as well, usually associated with cancer. Here we report the long‐term follow‐up of a patient with VGCC‐ab‐positive LEMS and a severe cerebellar syndrome but without evidence of cancer over 5 years. While conventional immunosuppressive therapy (steroids, azathioprine) failed, he improved with plasma exchange and consecutive treatment with rituximab. Muscle Nerve 40: 305–308, 2009
- 16 July 2009
- Published by Wiley in Muscle & Nerve
- Vol. 40 (2) , 305-308
Favorable response to rituximab in a patient with anti‐VGCC‐positive Lambert‐Eaton myasthenic syndrome and cerebellar dysfunction
Lambert‐Eaton myasthenic syndrome (LEMS) is an autoimmune disease that is characterized by impaired transmission across the neuromuscular junction due to autoantibodies directed against the presynaptic voltage‐gated calcium channels (VGCC‐ab). Clinical symptoms are usually characterized by proximal muscle weakness and mild dysautonomia. In some patients there are signs of cerebellar dysfunction as well, usually associated with cancer. Here we report the long‐term follow‐up of a patient with VGCC‐ab‐positive LEMS and a severe cerebellar syndrome but without evidence of cancer over 5 years. While conventional immunosuppressive therapy (steroids, azathioprine) failed, he improved with plasma exchange and consecutive treatment with rituximab. Muscle Nerve 40: 305–308, 2009